X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
breast cancer (45) 45
index medicus (44) 44
female (41) 41
humans (41) 41
oncology (41) 41
trastuzumab (39) 39
breast neoplasms - drug therapy (34) 34
chemotherapy (28) 28
resistance (26) 26
cancer (25) 25
breast neoplasms - pathology (22) 22
antineoplastic agents - therapeutic use (21) 21
her2 (21) 21
receptor, erbb-2 - metabolism (21) 21
antineoplastic combined chemotherapy protocols - therapeutic use (17) 17
middle aged (17) 17
skin and connective tissue diseases (17) 17
breast neoplasms - genetics (16) 16
neoadjuvant therapy (16) 16
breast neoplasms - metabolism (15) 15
therapy (15) 15
adult (14) 14
drug resistance (14) 14
drug resistance, neoplasm (14) 14
metastasis (13) 13
care and treatment (12) 12
neoadjuvant chemotherapy (12) 12
receptor, erbb-2 - antagonists & inhibitors (12) 12
receptor, erbb-2 - genetics (12) 12
aged (11) 11
antineoplastic agents (11) 11
genetic aspects (11) 11
lapatinib (11) 11
prognosis (11) 11
research (11) 11
antimitotic agents (10) 10
biomarkers (10) 10
epidermal growth factor (10) 10
monoclonal-antibody (10) 10
neoplasms (10) 10
open-label (10) 10
treatment outcome (10) 10
antibodies, monoclonal, humanized (9) 9
antibodies, monoclonal, humanized - administration & dosage (9) 9
drug therapy (9) 9
expression (9) 9
kinases (9) 9
adjuvant treatment (8) 8
analysis (8) 8
cancer therapies (8) 8
growth-factor receptor (8) 8
medicine & public health (8) 8
molecular targeted therapy (8) 8
signal transduction (8) 8
tumors (8) 8
adjuvant chemotherapy (7) 7
antibodies, monoclonal - therapeutic use (7) 7
antibodies, monoclonal, humanized - therapeutic use (7) 7
cell biology (7) 7
clinical trials (7) 7
development and progression (7) 7
disease-free survival (7) 7
health aspects (7) 7
monoclonal antibodies (7) 7
receptor (7) 7
trastuzumab resistance (7) 7
breast neoplasms - enzymology (6) 6
chemotherapy, adjuvant (6) 6
gene expression (6) 6
immunohistochemistry (6) 6
pathology (6) 6
phase-ii (6) 6
proteins (6) 6
quinazolines - administration & dosage (6) 6
review (6) 6
animals (5) 5
antineoplastic agents - pharmacology (5) 5
disease progression (5) 5
drug resistance, neoplasm - genetics (5) 5
efficacy (5) 5
genes (5) 5
growth (5) 5
hematology, oncology and palliative medicine (5) 5
medical prognosis (5) 5
microrna (5) 5
mutation (5) 5
neoplasm metastasis (5) 5
pathological complete response (5) 5
pharmacology & pharmacy (5) 5
plus adjuvant chemotherapy (5) 5
pten (5) 5
receptors, estrogen - metabolism (5) 5
targeted therapy (5) 5
1st-line treatment (4) 4
activation (4) 4
antibodies, monoclonal, humanized - pharmacology (4) 4
article (4) 4
biochemistry & molecular biology (4) 4
breast (4) 4
breast neoplasms - mortality (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Oncotarget, ISSN 1949-2553, 2015, Volume 6, Issue 35, pp. 37269 - 37280
Journal Article
by Wang, XL and Cai, LJ and Ye, F and Li, MQ and Ma, L and Geng, CZ and Song, ZC and Liu, YP
MEDICINE, ISSN 0025-7974, 09/2019, Volume 98, Issue 36, p. e16937
Metadherin (MTDH), also known as astrocyte elevated gene-1 (AEG-1), is an oncoprotein closely related to the development of breast cancer. However, few studies... 
GENE-1 | ACTIVATION | METASTASIS | breast cancer | PROLIFERATION | HER-2 | MTDH | neoadjuvant chemotherapy | MEDICINE, GENERAL & INTERNAL | PATHWAY | POOR-PROGNOSIS | RESISTANCE | METADHERIN | PROGRESSION
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 10/2014, Volume 147, Issue 3, pp. 513 - 525
Journal Article
BMC cancer, ISSN 1471-2407, 2013, Volume 13, Issue 1, pp. 241 - 241
Background: Chemotherapy with trastuzumab is widely used for patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer, but a... 
Neoadjuvant chemotherapy | TAMOXIFEN | ENDOCRINE THERAPY | SNP array | Estrogen receptor pathway | Relapse-free survival | LAPATINIB | AMPLIFICATION | ONCOLOGY | PROTEIN EXPRESSION | ERBB2 | RESISTANCE | CARCINOMAS | PI3K pathway | RECURRENCE | HER2 | Complete pathological response | TRANSCRIPTION FACTOR | Trastuzumab | Immunohistochemistry | Cyclophosphamide - administration & dosage | Receptors, Estrogen - metabolism | Oligonucleotide Array Sequence Analysis | Receptor, ErbB-2 - genetics | Humans | Receptor, ErbB-2 - metabolism | Phosphatidylinositol 3-Kinases - metabolism | Epirubicin - administration & dosage | Breast Neoplasms - metabolism | Receptors, Progesterone - metabolism | Breast Neoplasms - therapy | Antibodies, Monoclonal, Humanized - administration & dosage | Fluorouracil - administration & dosage | Female | Neoadjuvant Therapy | Chemotherapy, Adjuvant | Paclitaxel - administration & dosage | Kaplan-Meier Estimate | In Situ Hybridization, Fluorescence | Survival Rate | Gene Dosage | Signal Transduction - genetics | Disease-Free Survival | Breast Neoplasms - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Chromosome Aberrations | Polymorphism, Single Nucleotide | Receptors | Patient outcomes | Analysis | Estrogen | Breast cancer | Genetic aspects | Research | Drug therapy | Anthracyclines | Genes | Adjuvant treatment | Cancer patients | Epidermal growth factor | Phenols | Cytogenetics | Single nucleotide polymorphisms | Cancer | 1-Phosphatidylinositol 3-kinase
Journal Article
Journal Article
ANNALS OF ONCOLOGY, ISSN 0923-7534, 06/2019, Volume 30, Issue 6, pp. 927 - 933
Background HER2-positive (+) breast cancers, defined by HER2 overexpression and/or amplification, are often addicted to HER2 to maintain their malignant... 
ADJUVANT CHEMOTHERAPY | fluorescent in situ hybridization | MULTICENTER | ErbB2 receptor tyrosine kinase | PTEN | breast cancer | MECHANISMS | BREAST | IMPACT | THERAPY | ONCOLOGY | RESISTANCE | precision medicine | PIK3CA mutations | PTEN protein
Journal Article
Biotech Week, ISSN 1535-2757, 09/2016, p. 76
  According to the news reporters, the research concluded: "Collectively, these data provide a rationale for using miR-21 expression as a biomarker to select... 
Chemotherapy | Womens health | Oncology | Breast cancer | Drug resistance | Cancer therapies
Newspaper Article
Journal Article
Oncology, ISSN 0030-2414, 08/2012, Volume 83, Issue 4, pp. 218 - 227
Journal Article
Journal Article
Journal Article